By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD267 ‒ The latest in cancer therapeutics, diagnostics, and early detection | Keith Flaherty, M.D.
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
Flaherty and Attia on Converging Cancer Therapeutics, Immunotherapy, and Blood-Based Early Detection
- Attia lays out cancer's unusual toll across age groups, and the two discuss how hormones, obesity, smoking, and UV exposure drive different cancers, with Flaherty describing a growing divide between 'haves' like hormone-positive breast cancer and 'have-nots' like pancreatic cancer.
- Flaherty says long-term survival for overt metastatic solid tumors has risen from near zero to roughly 15%, with about half the gain from PD-1 antibody immunotherapy and the rest from molecularly targeted drugs.
- The conversation explains how cancers evade the immune system through neoantigens, PD-L1, suppressive cells, and a harsh microenvironment, and why cell therapies face specificity, cost, and scalability hurdles.
- Flaherty argues future gains will come from multimodal regimens combining targeted, metabolic, epigenetic, mutation-inducing, and immune approaches rather than a single drug.
- Because the same drugs work far better against microscopic residual disease than overt metastases, both speakers see blood-based early detection, such as circulating tumor DNA tests, as the pivotal opportunity, along with a call for better access to expert opinion.
IDEAS WORTH REMEMBERING
5 ideasProgress against metastatic solid tumors has been real but concentrated in few mechanisms.
Flaherty puts ten-year survival for overt metastatic disease at about 15%, possibly heading toward 20%, with half of the gain from PD-1 antibodies and 52 FDA approvals spanning only about 19 unique mechanisms.
Cancers escape the immune system in layered ways.
Flaherty describes PD-L1 expression, altered interferon pathways inside tumor cells, recruited suppressive immune cells and fibroblasts, and a low-oxygen, nutrient-poor microenvironment that all blunt T cells.
Engineered T cell therapy is limited by the need for cancer-specific targets.
CD19 therapy works because patients can survive without B cells, but common epithelial cancers need markers truly specific to tumors, and Flaherty notes cost and manufacturing also stand in the way.
Future regimens will likely combine mechanisms from different categories.
Flaherty expects a multi-drug regimen drawing from different classes, tailored to each patient, including metabolic and epigenetic drugs and mutation-inducing chemotherapy paired with targeted therapy to boost immune recognition.
The same drugs work much better against microscopic disease.
Flaherty offers two hypotheses: less clonal heterogeneity and a more intact immune system with fewer defenses, which helps the immune system finish off the last cells.
WORDS WORTH SAVING
5 quotesA single approach, um, has accounted for half that number. It's astounding.
— Dr. Keith Flaherty
The ones that produce powerful immune responses, well, guess what? Those cancers never became cancers in the first place. They got wiped out.
— Dr. Keith Flaherty
It's not gonna be four therapeutic maneuvers all in column A, right? Or four in column D. It's like one from A, one from B, one from C, one from D. That's the type of four drug regimen that's gonna eradicate cancer, and it's not gonna be one cocktail for all patients.
— Dr. Keith Flaherty
There's nobody who's listening to this podcast whose life has not been affected by cancer. That wouldn't be possible.
— Peter Attia
It's the crossing of those wires. That's what's really gonna massively get us towards the path of having a much, much higher percentage of patients who are 10 year survivors.
— Dr. Keith Flaherty
High quality AI-generated summary created from speaker-labeled transcript.
